NCT05723588 Neuroimaging Correlates and Feasibility of Transcranial Magnetic Stimulation (TMS) to Improve Smoking Cessation Outcomes in Veterans With Comorbid PTSD
| NCT ID | NCT05723588 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | VA Office of Research and Development |
| Condition | Tobacco Use Disorder |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2023-10-31 |
| Primary Completion | 2027-11-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 50 participants in total. It began in 2023-10-31 with a primary completion date of 2027-11-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Tobacco use is the number one preventable cause of the death in the United States, and is high among US Veterans, and those who have experienced trauma are more likely to smoke. Despite the efficacy of current evidence-based treatments for smoking cessation, there is a critical need for alternative treatments. This project seeks to evaluate the feasibility and effectiveness of a smoking cessation treatment for Veterans with posttraumatic stress disorder (PTSD) who smoke. The treatment combines smoking cessation counseling, nicotine replacement therapy (e.g., nicotine gum), and repetitive transcranial magnetic stimulation (rTMS). rTMS is a noninvasive brain stimulation treatment that has been cleared by the Food and Drug Administration for smoking cessation in adults.
Eligibility Criteria
Inclusion Criteria: * Is a US Veteran * Meets DSM-5 criteria for tobacco use disorder * Is between the ages of 18 and 75 * Smokes an average of 10 cigarettes per day for the past 6 months, with carbon monoxide (CO) level \> 6 ppm * Is willing to attempt smoking cessation * Meets DSM-5 criteria for current PTSD diagnosis * Speaks, reads and writes English * Is willing to sign a Duke consent for those portions of the study that occur at Duke * Has been stable on psychotropic medications for at least three months Exclusion Criteria: * Has had a substance use disorder other than tobacco in the preceding 3 months * Has a history of myocardial infarction in the past 6 months or has another contraindication to NRT * Has a contraindication to TMS or MRI * Personal or family history of a seizures or epilepsy * History of neurological condition that increases the risk of seizures including stroke or transient ischemic attack, cerebral aneurysm, or severe traumatic brain injury from a penetrating head injury, loss of consciousness \> 20 minutes at time of traumatic injury, requiring an anticonvulsant medication for seizures, and/or found to have encephalomalacia on baseline MRI * Structural brain lesion, or prior brain surgery * Ferromagnetic metal in head (including shrapnel) * Implanted devices that may be affected by MRI or TMS (pacemaker, medication pump, cochlear implant, implanted deep brain stimulator) * Is pregnant (to be determined at Duke) * Is unable to complete study procedures * Is currently prescribed bupropion and/or varenicline * Uses other forms of nicotine such as cigars, pipes, chewing tobacco, or vaping * Is unable to provide informed consent due to a major neurocognitive disorder or other reason * Meets criteria for a primary psychotic disorder or current manic episode * Is currently imprisoned or psychiatrically hospitalized * Has previously received rTMS
Contact & Investigator
Jonathan R Young, MD
PRINCIPAL INVESTIGATOR
Durham VA Medical Center, Durham, NC
Frequently Asked Questions
Who can join the NCT05723588 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Tobacco Use Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT05723588 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT05723588 currently recruiting?
Yes, NCT05723588 is actively recruiting participants. Contact the research team at jonathan.young14@va.gov for enrollment information.
Where is the NCT05723588 trial being conducted?
This trial is being conducted at Durham, United States.
Who is sponsoring the NCT05723588 clinical trial?
NCT05723588 is sponsored by VA Office of Research and Development. The principal investigator is Jonathan R Young, MD at Durham VA Medical Center, Durham, NC. The trial plans to enroll 50 participants.